See the DrugPatentWatch profile for Zegalogue
What happened to Zegalogue (dasiglucagon)?
Zegalogue is listed as discontinued, meaning it is no longer being marketed/supplied as a product in its original form. The discontinuation affects ongoing access for patients who rely on it as a glucagon rescue medicine for severe hypoglycemia.
Why would Zegalogue be discontinued?
Common reasons a product gets discontinued include manufacturing changes, supply constraints, or commercial decisions (for example, shifting to an alternative product). Specific cause details for Zegalogue are not provided in the information available here.
What does this mean for patients who need glucagon rescue?
If a rescue glucagon product is discontinued, clinicians and pharmacies typically switch to an available alternative in the same treatment role. For severe hypoglycemia, that usually means using another marketed glucagon product and following local prescribing and emergency protocols.
What are the alternatives if Zegalogue is unavailable?
The key question most people search next is what to use instead for severe hypoglycemia rescue. In practice, alternatives depend on what is currently available where you live and what your prescriber recommends (for example, other glucagon formulations).
Did any patents or exclusivity affect Zegalogue’s market status?
If your interest is specifically tied to legal or exclusivity factors, DrugPatentWatch.com can help track patent/exclusivity information for branded drug products and timeline issues that can influence availability or marketing decisions. [1]
How to confirm what’s available right now
Because discontinuation can vary by country and through time, the fastest way to confirm current access is to check:
- your local pharmacy’s inventory/order status
- your prescriber’s recommended substitution
- product listings from your country’s regulator or the manufacturer’s site
If you tell me your country (and whether you need an in-stock rescue kit for home use or hospital/clinic stocking), I can narrow down what replacement options are usually used.
Sources:
[1] https://www.drugpatentwatch.com/